• Clinical data 90%
  • Efficacy 80%
  • Security 70%
  • Toxicity 30%

Withania somnifera
Radix Withaniae

Synonyms

Physalis somnifera L.

General appearance

Straight and unbranched, the thickness varying with age. The main roots bear fibre-like secondary roots. The outer surface of the root is buff to grey-yellow with longitudinal wrinkles. The crown consists of 2–6 remains of the stem base. The base of the stem is green, variously thickened, cylindrical and longitudinally wrinkled. The roots break with a short uneven fracture.

Major chemical constituents

The major characteristic constituents are steroidal lactones collectively known as “withanolides” including withaferin A, 27 deoxywithaferin A, withanolide D, withanosides I–XI, and withasomniferols A–C. Alkaloids constitute the other major group of compounds found in this plant material. Among the alkaloids found in the root are anaferine, anahygrine, cuscohygrine, dl-isopelletierine, 3-tropyltigloate, tropane-3-ol, 3- tigloyl-oxy-tropane and tropine. Also present are saponins including sitoindosides VII–X.

Medicinal uses

Uses supported by clinical data
As an antistress agent to improve reaction time.
Uses described in pharmacopoeias and well established documents
As a general tonic to increase energy, improve overall health and prevent disease in athletes and the elderly.
Uses described in traditional medicine
Treatment of bronchitis, dyspepsia, impotency, scabies and ulcers.

Pharmacology

Experimental pharmacology

Antistress activity

The activity of a standardized extract of the root (1:1 aqueous ethanol fraction containing the withanolide glycosides and withaferin A at a concentration of 28–30%) was investigated in a rat model of chronic stress. A mild, unpredictable foot-shock was administered once daily for 21 days to rats. These chronic stress-induced perturbations were attenuated by the intragastric administration of the crude drug, at a dose of 25.0 and 50.0 mg/kg body weight (bw) given 1 h before foot-shock for 21 days.
In a mouse model of chronic stress, the antioxidant effects of the root were assessed in the forced swimming test. Biochemical analysis revealed that chronic swimming significantly increased lipid peroxidation and decreased glutathione levels in the brains of mice. The animal models also showed decreased levels of antioxidant defence enzymes, superoxide dismutase and catalase. Intragastric treatment with an extract of the crude drug, at a dose of 100.0 mg/kg bw significantly reduced lipid peroxidation and restored the glutathione levels decreased by chronic swimming in mice. Further, the treatment increased levels of superoxide dismutase in the forebrain and increased levels of catalase.
A withanolide-free aqueous fraction from the root (13 kg plant material in 70% ethanol, aqueous fraction) was evaluated for putative antistress activity. Intragastric administration of the preparation to immunocompromised mice for 7 days increased antibody production with a median effective dose of 40 mg/kg bw. Thus, the fraction exhibited significant antistress activity in a dose-related manner. The same fraction was protective against chemically and physically induced stress in rats and mice.
Intragastric administration of sitoindosides IX and X, at a dose range of 50–200.0 mg/kg bw also produced antistress activity in albino mice and rats, and augmented learning acquisition and memory retention in both young and old rats.

Anti-inflammatory activity

Numerous investigations have assessed the anti-inflammatory effects of the crude drug in vitro and in vivo. In one study, a suspension of powdered root (1 g/kg suspended in 2% acacia gum, 50 mg/ml) administered intragastrically to rats for 3 days, 1 hour before the injection of Freund’s complete adjuvant, reduced inflammation. Many serum proteins such as 2-glycoprotein, a major acute inflammatory phase protein and pre-albumin were decreased, indicating a reduction in acute inflammation. In another study by the same research group, 1 g/kg of the root suspension reduced the 2-macroglobulin in the serum of rats given subplantar injection of carrageenan suspension.
In one study, air pouch granuloma was induced by subcutaneous injections of 4 ml of carrageenan on the dorsum of rats which had been subcutaneously injected 1 day previously with 6 ml of air on the dorsum. The powdered crude drug was administered by gastric lavage at a dose of 1 g/kg bw for 3 days. Radioactive sodium sulfate was injected intraperitoneally on day 9 and the incorporation of radio labelled sulfur in glycosaminoglycan, oxidative phosphorylation (ADP/O ratio), mg2+- dependent-ATPase enzyme activity and succinate dehydrogenase activity were determined in the mitochondria of the granuloma tissue. Administration of the root decreased the glycosaminoglycan content of the granuloma tissue by 92%, compared with 43.6% following treatment with hydrocortisone (15.0 mg/kg bw) and had no effect following treatment with phenylbutazone (100.0 mg/kg bw).
In a further study, the effect of oral administration of the crude drug (root powder, 1 g/kg bw, daily for 15 days) on paw swelling and bony degenerative changes in Freund’s complete adjuvant-induced arthritis in rats was assessed. Intragastric administration of the powdered root to the rats caused a significant reduction in both paw swelling and degenerative changes as observed by radiological examination. The reductions were better than those produced by the reference drug, hydrocortisone (15.0 mg/kg bw).
Daily intragastric administration of 1.0 g/kg bw of the powdered root suspended in 2% gum acacia, was given 1 hour before the induction of inflammation by injection of Freund’s complete adjuvant in rats for 3 days. Phenylbutazone (100.0 mg/kg bw) was administered to another group of animals as a positive control. Assessment of acute phase reactants of the blood showed changes in the concentration of  2-glycoprotein, major acute phase 1-protein, and pre-albumin in rats with inflammation, while in animals treated with the powdered root, the 2-glycoprotein and acute phase protein were decreased to undetectable levels.
Intragastric administration of the root, at doses of 500, 1000, 1500 or 1200 mg/kg bw, given orally as a suspension 3–4 hours prior to induction of inflammation, also caused a dose-dependent suppression of 􀁁 2-macroglobulin (an indicator for anti-inflammatory drugs) in the serum of rats inflamed by subplantar injection of carrageenan. The maximum effect (about 75%) was seen at 1.0 g/kg bw. Actual measurements of inflammation were not made. Glycowithanolides and a mixture of sitoindosides IX and X isolated from the crude drug were evaluated for their immunomodulatory and central nervous system effects (antistress and improvements to memory and learning) in mice and rats. Both mixtures of compounds led to mobilization and activation of peritoneal macrophages, phagocytosis and increased activity of the lysosomal enzymes.

Anti-ischaemic activity

An in vivo study assessed the effect of the crude drug as a prophylactic treatment against stroke using the middle cerebral artery occlusion model in rats. Two groups of rats were pretreated with a hydroalcoholic extract of the crude drug (1.0 g/kg, administered by gastric lavage) for 15 or 30 days. The rats were then subjected to focal ischaemia by occlusion of the middle cerebral artery using an intraluminal thread. After 2 hours of middle cerebral artery occlusion, reperfusion was allowed by retracting the thread and the animals were assessed for ischaemic changes 30 min after reperfusion. Twenty-four hours later, rats were subjected to motor performance tests and were subsequently killed to enable estimation of the marker of oxidative stress, malondialdehyde. Significant motor impairment, with elevated levels of malondialdehyde, was observed in middle cerebral artery-occluded control rats. Treatment with the crude drug for 30 days prevented motor impairment and significantly decreased the raised levels of malondialdehyde compared with rats treated with the vehicle. Treatment also attenuated the percentage hemispheric lesion area in diffusion-weighted imaging (17 ± 2%) compared with the vehicle treated middle cerebral artery-occluded group (30 ± 4%).
A study was conducted to evaluate the cardioprotective potential of a hydro-alcoholic extract of the roots, by assessing the effects of treatment on haemodynamic, histopathological and biochemical parameters in isoprenaline- (isoproterenol-) induced myocardial necrosis in rats and to compare the effects with those of vitamin E. Rats were divided into six main groups: sham, isoprenaline control, Withania somnifera and vitamin E controls and Withania somnifera and vitamin E treatment groups.
The root extract was administered at doses of 25, 50 and 100 mg/kg, and vitamin E at a dose of 100 mg/kg, orally for 4 weeks. On days 29 and 30, the rats in the isoprenaline control group and the Withania somnifera and vitamin E treatment groups were given isoprenaline (85 mg/kg), subcutaneously at an interval of 24 hours. On day 31, haemodynamic parameters were recorded before the animals were killed, and the hearts were subsequently removed and subjected to histopathological and biochemical studies. A significant decrease in glutathione (p < 0.05), activities of superoxide dismutase, catalase, creatinine phosphokinase and lactate dehydrogenase (p < 0.01) as well as an increase in the level of the lipid peroxidation marker malonyldialdehyde (p < 0.01) was observed in the hearts of rats in the isoproterenol control group as compared to rats in the sham control group. Treatment with the root extract exerted a strong protective effect against isoprenaline-induced myonecrosis in rats. The dose of 50 mg/kg bw of the root extract had the greatest cardioprotective effect of the treatments studied.

Antioxidant activity

Dried ethanol extracts of the roots were tested for their total antioxidant activity in the iron (Fe3+) reducing assay, and found to be potent reductants of Fe3+ at pH 5.5. In an in vivo study, the powdered roots were assessed for their ability to protect neurons against excitotoxic lesions induced by kainic acid in mice. Mice were anaesthetized with ketamine and xylazine and kainic acid was administered by intra-hippocampal injections.
The results showed an impairment of the function of the hippocampus region of brain after injection of kainic acid, and lipid peroxidation and protein carbonyl content were significantly increased in comparison with control animals (p < 0.05). The extract given 3 weeks prior to injections of kainic acid resulted in a decrease in neurotoxicity and measures of lipid peroxidation and protein carbonyl declined. The results of this study suggest that the crude drug mitigates the effects of excitotoxicity and oxidative damage in hippocampus by its antioxidative properties.
The glycowithanolides isolated from the crude drug were investigated for their preventive effect on the animal model of tardive dyskinesia, induced by once daily administration of the neuroleptic, haloperidol, for 28 days. Involuntary orofacial movements chewing movements, tongue protrusion and buccal tremors were assessed as parameters of tardive dyskinesia.
Intragastric administration of 100.0 and 200.0 mg of the root, concomitantly with haloperidol, for 28 days inhibited the induction of the neuroleptic tardive dyskinesia.
The effects of the roots against oxidative stress in haloperidol-induced orofacial dyskinesia (haloperidol-induced vacuous chewing movements and tongue protrusion) were assessed in rats. Animals were treated for 21 days with intraperitoneal haloperidol (1 mg/kg); on day 22, vacuous chewing movements and tongue protrusions were counted during a 5-minute observation period. Coadministration of the extract (100– 300 mg/kg bw) dose-dependently reduced haloperidol-orofacial dyskinesia.
Biochemical analysis revealed that chronic treatment with haloperidol significantly increased lipid peroxidation and decreased forebrain levels of glutathione and the antioxidant defence enzymes, superoxide dismutase and catalase. Coadministration of the crude drug extract significantly reduced the lipid peroxidation and significantly reversed the decrease in forebrain superoxide dismutase and catalase levels, but had no significant effect on the haloperidol-induced decrease in forebrain glutathione levels.
The sitoindosides VII–X and withaferin A (glycowithanolide), were tested for antioxidant activity using the major free-radical scavenging enzymes, superoxide dismutase, catalase and glutathione peroxidase levels in the rat brain frontal cortex and striatum. Active glycowithanolides of Withania somnifera (10.0 or 20.0 mg/kg bw) were administered by intraperitoneal injection once daily for 21 days to groups of six rats. Dose-related increases in all enzymes were observed; the increases were comparable to those seen following administration of deprenyl (2 g/kg bw intraperitoneally), indicating that the crude drug has an antioxidant effect in the brain which may be responsible for its diverse pharmacological properties.
In another study, an aqueous suspension of the crude drug was evaluated for its effect on stress-induced lipid peroxidation in mice and rabbits. Levels of lipid peroxidation in the blood were increased by intravenous administration of lipopolysaccharides from Klebsiella pneumoniae and peptidoglycans from Staphylococcus aureus. Simultaneous intragastric administration of the extract (100.0 mg/kg bw) prevented an increase in lipid peroxidation.
In another study, the powdered root was administered to mice at a dose of 0.7 and 1.4 g/kg bw, for 15 and 30 days, to determine its effects on lipid peroxidation, superoxide dismutase and catalase activities. Thirty days of treatment produced a significant decrease in lipid peroxidation, and an increase in both superoxide dismutase and catalase activities.
The effect of an extract of the crude drug on the regulation of lead toxicity and lipid peroxidative activity was investigated in liver and kidney tissues of rodents. Lead treatment of the animals for 20 days enhanced hepatic and renal lipid peroxidation, whereas administration of the extract at doses of 0.7 g/kg bw and 1.4 g/kg bw together with equivalent doses of lead acetate for 20 days significantly decreased lipid peroxidation and increased the activities of antioxidant enzymes, such as superoxide dismutase and catalase.
An in vivo study examined the attenuating effect of extracts of the root and of aloe vera on prevention of hippocampal and cortical cell degeneration due to oxidative damage in mice with streptozotocin-induced diabetes.
Doses of both plant extracts given to experimental animals were based on the evaluation of their total antioxidant activity and also their potency to reduce Fe3+. Lipid peroxidation and protein carbonyl were assayed in both regions of the brain and the changes in memory and motor behavioural functions in diabetic and control mice were observed. The resultsshowed a significant increase in lipid peroxidation and protein carbonyl in the hippocampus and cortical regions of mice with streptozotocininduced diabetes, as well as a significant impairment in both motor and memory behavioural functions in diabetic mice. However, when diabetic mice were supplemented with the extracts of the root and with aloe vera, the oxidative damage in both brain regions was reduced as marked by a significant decline in both lipid peroxidation and protein carbonyl. The combination of extracts of root and aloe vera was more effective in reducing oxidative damage in brain regions than either of the plant extracts given alone. The combination of the extract and the aloe vera lowered the blood glucose level in mice with streptozotocin-induced diabetes. Memory impairment and motor dysfunction were also lessened by supplementation with the plant extracts.

Chemopreventive activity

The chemopreventive effect of an alcohol extract of the crude drug on 7,12-dimethylbenz[a]anthracene (DMBA)-induced skin cancer was investigated in mice. The skin lesions were induced by the twice-weekly topical application of DMBA for 8 weeks to the shaved backs of mice. The alcohol extract was administered at the maximum oral tolerated dose of 400.0 mg/kg bw three times per week on alternate days 1 week before  DMBA application and treatment was continued for 24 weeks. The results showed a significant decrease in incidence and average number of skin lesions in mice that received the extract compared to those treated with DMBA alone at the end of week 24. A significant impairment was noticed in the levels of reduced glutathione, malondialdehyde, superoxide dismutase, catalase, glutathione peroxidase and glutathione S-transferase in skin lesions of DMBA-treated control mice compared with vehicle treated mice. These parameters returned to near normal following administration of the crude drug to DMBA-treated mice.
Another chemopreventive study of an alcohol extract of the crude drug against 20-methylcholanthrene-induced fibrosarcoma tumours in mice was performed. A single subcutaneous injection of 20-methylcholanthrene into the thigh region of the mice produced a high incidence (96%) of tumours. Intragastric administration of the extract at a dose of 400.0 mg/kg bw (1 week before injecting 20 methylcholanthrene and continued until 15 weeks thereafter) significantly reduced the incidence and volume of tumours and enhanced the survival of the mice, compared with mice injected with 20-methylcholanthrene. The tumour incidence was also delayed in the group treated with the extract when compared with mice injected with 20-methylcholanthrene without pretreatment with the extract. Liver biochemical parameters revealed a significant modulation of reduced glutathione, lipid peroxides, glutathione S-transferase, catalase and superoxide dismutase in mice treated with the extract compared with mice injected with 20-methylcholanthrene.

Effects on memory and cognition

An aqueous suspension (100 mg/ml of powdered root suspended in 2% acacia gum and water) was assessed for its effects on improving shortterm memory by reversing the effects of memory deficits induced by scopolamine and amnesia induced by electroconvulsive shock. Daily administration of 200 mg/kg bw of the suspension significantly reversed the scopolamine-induced delay in latency for the animals to reach the shock free zone and the number of errors in the passive avoidance stepdown test (p < 0.001). Treatment of the animals with 100 mg/kg bw of the suspension produced a significant reduction in latency to reach the shock free zone (p < 0.05).
Sitoindosides VII–X and withaferin A were isolated from an aqueous methanol extract of the roots. Rats were treated with 40 mg/kg bw (intraperitoneally) of an equimolar mixture of these compounds for 7 days and the anticholinesterase activity was determined in brain slices. Acetylcholinesterase activity was increased in the lateral septum and globus pallidus indicating a possible enhancement of cognition.
Withanolides isolated from the crude drug inhibited acetylcholinesterase and butyrylcholinesterase enzymes in a concentration-dependent fashion with IC50 values ranging between 20.5 and 85.2 􀁍M for acetylcholinesterase and butyrylcholinesterase. Lineweaver Burk as well as Dixon plots and their secondary replots indicated that the compounds were linear mixed-type inhibitors of acetylcholinesterase and non-competitive inhibitors of acetylcholinesterase with Ki (dissociation constant) values ranging between 20.0 and 45.0 M. All compounds were found to be noncompetitive inhibitors of butyrylcholinesterase with Ki values ranging between 27.7 and 90.6 M.

Immune stimulant activity

The effects of the root were investigated in mice with myelosuppression induced by cyclophosphamide, azathioprin or prednisolone. Administration of the root (100 mg/kg bw) prevented myelosuppression in mice treated with all three immunosuppressive drugs tested. A significant increase in haemoglobin concentration (p < 0.01), red blood cell count (p < 0.01), white blood cell count (p < 0.05), platelet count (p < 0.01), and body weight (p < 0.05) was observed in treated mice as compared with untreated (control) mice.
The effect of the crude drug on the cellular immune responses was studied in normal and in tumour-bearing animals. Intraperitoneal injection of five doses of an extract of the crude drug (20 mg/dose/animal) enhanced the proliferation of lymphocytes, bone marrow cells and thymocytes in response to mitogens. Both phytohaemagglutinin and concanavalin A mitogens administered concomitantly with crude drug treatment doubled the proliferation of lymphocytes, bone marrow cells and thymocytes. Splenocytes treated with the crude drug together with the mitogen led to a six-fold increase in lymphocyte proliferation. Natural killer cell activity was stimulated by the crude drug extract in both normal and tumour-bearing animals and it was found to be earlier than in the controls (48.92% cell lysis). Antibody dependent cellular cytotoxicity was found to be enhanced in the group treated with the crude drug on the ninth day after treatment (65% cell lysis). These authors have also reported that intraperitoneal administration of a 70% methanol extract of the roots to mice at a dose of 20 mg/animal enhanced total white blood cell count on day 10 after the administration of a single dose; bone marrow cellularity also increased, and the delayed-type hypersensitivity reaction (Mantoux test) was reduced.
The immunomodulatory effects of extracts of the crude drug (suspensions in carboxymethyl cellulose) were investigated in mice to measure their effects on immune hyper-reactivity. The animal models used included antibody-mediated immune hyper-reactivity, as seen in active paw anaphylaxis with disodium chromoglycate and cell-mediated immune hyper-reactivity using the delayed-type hypersensitivity model with cyclophosphamide. The immunomodulatory effect was assessed in IgEmediated anaphylaxis as the reduction of ovalbumin induced paw oedema in animals treated with the crude drug suspension at doses of 150 and 300.0 mg/kg bw. The positive control drug used was disodium chromoglycate. Potentiation of the delayed-type hypersensitivity reaction was observed in animals treated with cyclophosphamide at a dose of 20.0 mg/ kg bw, and the crude drug suspensions at a dose of 300–1000.0 mg/kg bw. A significant increase in white blood cell counts and platelet counts was observed in animals treated with the crude drug. A protective effect against cyclophosphamide-induced myelosuppression was observed in animals treated with suspensions of the crude drug at doses of 300– 1000.0 mg/kg bw, and a significant increase in white blood cell counts and platelet counts was observed. Cyclophosphamide-induced immunosuppression was counteracted by treatment with the same crude drug suspension.
Treated animals showed an increase in haemagglutinating antibody responses and haemolytic antibody responses towards sheep red blood cells.
In a study in mice, intraperitoneal administration of a methanol extract of the root (20.0 mg/kg bw) was found to significantly reduce leukopaenia induced by treatment with cyclophosphamide. On the twelfth day the total white blood cell count in the group treated with cyclophosphamide was 3720 cells/mm2 and that of the group that received cyclophosphamide together with the root was 6120 cells/mm2. Treatment with the root and cyclophosphamide significantly increased the bone marrow cellularity (13.1 × 106 cells/femur) compared to the group treated with cyclophosphamide alone (8 × 106 cells/femur) (p < 0.001). Administration of the extract increased the number of alpha-esterase positive cells in the bone marrow of animals treated with cyclophosphamide, compared with the animals in the group treated with cyclophosphamide alone (687/4000 cells).
The mechanism underlying the immunostimulant effect of a methanol extract of the root was investigated by assessing nitric oxide production in J774 macrophages. At concentrations of 1–256 μg/ml the extract produced a significant and concentration-dependent increase in nitric oxide production, an effect which was abolished by N(G)nitro-L-arginine methyl ester, a non-selective inhibitor of nitric oxide synthase; dexamethasone, an inhibitor of protein synthesis; and N(alpha-p)-tosyl-L-lysine chloromethyl ketone, an inhibitor of nuclear factor-kappa-activation. In addition, Western blot analysis showed that the methanol extract increased, in a concentration dependent fashion, expression of inducible nitric oxide synthase protein. The results suggest that the crude drug may induce the synthesis of inducible nitric oxide synthase expression, probably by acting at the transcriptional level, and the increased nitric oxide production by macrophages could account, at least in part, for the immunostimulant properties.

Neuroprotective activity

Eighteen compounds isolated from a methanol extract of the crude drug enhanced neurite outgrowth in human neuroblastoma cells. Double immunostaining was performed in rat cortical neurons using antibodies to phosphorylated nuclear factor-H as an axonal marker, and to mitogen activated protein kinase as a dendritic marker. In cells treated with withanolide A, the length of nuclear factor-H-positive processes was significantly increased compared with that of vehicle-treated cells, whereas the length of mitogen activated protein kinase positive processes was increased by withanosides IV and VI. These results suggest that axons are predominantly extended by withanolide A, and dendrites by withanosides IV and VI.
The anti-parkinsonian effects of a root extract were investigated in rats pretreated with 100, 200 and 300 mg/kg bw of the root extract orally for  3 weeks. On day 21, 2 μl of 6-hydroxydopamine was infused into the right striatum while animals in the sham-operated group received 2 l of the vehicle solvent. Three weeks after being injected with 6-hydroxydopamine, the rats were tested for neurobehavioural activity and 5 weeks after treatment they were killed for the estimation of lipid peroxidation, reduced glutathione content, activities of glutathione S-transferase, glutathione reductase, glutathione peroxidase, superoxide dismutase and catalase, catecholamine content, dopaminergic D2-receptor binding and tyrosine hydroxylase expression. The root extract reversed all the parameters in a dose-dependent manner indicating a potential for preventing neuronal injury in Parkinson disease.

Toxicity

In one study of its effects on the central nervous system, a 2% aqueous suspension of the powdered root, an alkaloid-containing extract of the root prepared in 10% propylene glycol using 2% gum acacia as the suspending agent, was used to determine acute toxicity. The acute median lethal dose (LD50) was 465.0 mg/kg bw in rats and 432.0 mg/kg bw in mice. In an antistress-effect study, the acute toxicity of aqueous-methanol extracts of the crude drug and equimolar combinations of sitoindosides VII and VIII (SG-I) and withaferin-A (SG-2) were studied. The acute LD50 of SG-1 and SG-2 administered intraperitoneally to mice was 1076.0 mg/kg bw and 1564.0 mg/kg bw, respectively.
In one study of the effects of chronic administration, the root was boiled in water and administered to rats in their drinking-water for 8 months while monitoring body weight, general toxicity, well-being, number of pregnancies, litter size and weight of progeny. The estimated dose given was 100.0 mg/kg bw per day. In the second part of the study, an estimated dose of 200 mg/kg bw per day was given for 4 weeks as above while monitoring body temperature, body weight, cortisol value in heparinized plasma and ascorbic acid content of the adrenals. The liver, spleen, lungs, kidneys, thymus, adrenals and stomach were examined histopathologically and were all found to be normal.
The initial average body weights of the animals in the group treated with the crude drug (100.0 mg/kg bw per day) and in the control group on day 1 were 91 g and 106 g, which, after 4 weeks, had increased to 185 g (103%) and 178 g (67.9%), respectively. The rats treated with the crude drug gained more weight than those in the control group (no p value given). The percentage weight gain after 8 weeks of the same Withania somnifera treatment was 227% for the animals in the treated group and 145.3% for those in the control group. The relative body weight gain was significantly greater in the group treated with the crude drug than in the control group (p < 0.001). While it is not clear when the rats were mated, the average weights of the progeny at 1 month of age were 70 g and 45 g in the crude-drug-treated and control groups, respectively, indicating healthier progeny in the treated group. In the 4-week study, the weight gain in the animals in the treated group was comparable to that of those in the control group. The body temperature of animals in the group treated with the crude drug was 1.7 ºC lower than in the control animals. The treatment caused an increase in lung and liver weights and a decrease in adrenocortical activity as was evident from the reduction in adrenal weight and a significant reduction in plasma cortisol (p < 0.001). Histopathologically, all organs were normal, and no toxicity was observed.

Clinical pharmacology

A double-blind, placebo-controlled clinical trial assessed the effects of the root (250 mg twice daily) on psychomotor performance in 30 healthy volunteers. The effects were compared with those of Panax ginseng (100 mg twice daily). Test parameters included tapping, cancellation test, mental mathematical calculations, logical deductions, choice reaction times and auditory reactions. The performance of both groups was superior to that of subjects who received a placebo and the performance of subjects given the crude drug was superior to that of those given Panax ginseng after 40 days of treatment.

Adverse reactions

May cause nausea, vomiting and diarrhoea.

Contraindications

Due to the lack of safety data and the fact that the crude drug has been used in traditional medicine to induce abortion, its use during pregnancy or breastfeeding is contraindicated.

Warnings

No information was found.

 

News and Journals

References
1. The Ayurvedic pharmacopoeia of India. Part I, Vol. I, 1st ed. New Delhi,
Government of India Ministry of Health and Family Welfare, Department of
Indian Systems of Medicine and Homeopathy, 1990 (reprinted 2001).
2. Unani pharmacopoeia of India. Part I, Vol. I. New Delhi, Ministry of Health
and Family Welfare, Department of Indian Systems of Medicine and Homeopathy,
1999.
3. Al-Yahya MA et al. Saudi plants. A phytochemical and biological approach.
Riyadh, King Abdulaziz City for Science and Technology, King Saud University,
1990.
389
Radix Withaniae
4. Upton R, Petrone C, Swisher D, eds. Ashwagandha root. Withania somnifera.
In: American herbal pharmacopeia. Santa Cruz, CA, American Herbal
Pharmacopeia, 2000.
5. Farnsworth NR, ed. NAPRALERT database. Chicago, University of Illinois
at Chicago, IL (an online database available directly through the University
of Illinois at Chicago or through the Scientific and Technical Network [STN]
of Chemical Abstracts Services), 30 June 2005.
6. Nadkarni AK, ed. Dr. K.M. Nadkarni’s Indian materia medica. Vol. 1. Bombay,
Popular Prakashan, 1976.
7. Parsa A. Flore de l’Iran. Vol. 16. Tehran, University of Tehran, 1997.
8. Bruneton J. Pharmacognosy, phytochemistry, medicinal plants. Paris, Lavoisier,
1995.
9. Arambewela L, Silva R. (eds). Sri Lankan medicinal plant: monographs and
analysis. Vol. 4. Withania somnifera. Colombo, Industrial Technology Institute
(CISIR) and National Science Foundation, 1999:1–26.
10. Ganzera M, Choudhary MI, Khan IA. Quantitative HPLC analysis of withanolides
in Withania somnifera. Fitoterapia, 2003, 74:68–76.
11. WHO guidelines for assessing quality of herbal medicines with reference to
contaminants and residues. Geneva, World Health Organization, 2007.
12. European pharmacopoeia, 5th ed. Strasbourg, Directorate for the Quality of
Medicines of the Council of Europe (EDQM), 2005.
13. Guidelines for predicting dietary intake of pesticide residues, 2nd rev. ed. Geneva,
World Health Organization, 1997 (WHO/FSF/FOS/97.7).
14. Zhao J et al. Withanolide derivatives from the roots of Withania somnifera
and their neurite outgrowth activities. Chemical and Pharmaceutical Bulletin,
2002, 50:760–765.
15. Karnick CR. Pharmacopoeial standards of herbal plants. Delhi, Sri Satguru
Publications, 1994.
16. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of
Withania somnifera (Ashwagandha): A review. Alternative Medicine Review,
2000, 5:334–346.
17. Bhattacharya SK, Muruganandam AV. Adaptogenic activity of Withania
somnifera: an experimental study using a rat model of chronic stress. Pharmacology
Biochemistry and Behavior, 2003, 75:547–555.
18. Singh A et al. Effect of natural and synthetic antioxidants in a mouse model
of chronic fatigue syndrome. Journal of Medicinal Food, 2002, 5:211–220.
19. Singh B, Chandan BK, Gupta DK. Adaptogenic activity of a novel withanolide-
free aqueous fraction from the roots of Withania somnifera Dun. (Part
II). Phytotherapy Research, 2003, 17:531–536.
20. Anbalagan K, Sadique J. Influence of an Indian medicine (Ashwagandha) on
acute-phase reactants in inflammation. Indian Journal of Experimental Biology,
1981, 19:245–249.
21. Anbalagan K, Sadique J. Role of prostaglandins in acute phase proteins in
inflammation. Biochemical Medicine, 1984, 31:236–245.
390
WHO monographs on selected medicinal plants
22. Begum VH, Sadique J. Effect of Withania Somnifera on glycosaminoglycan
synthesis in carrageenin-induced air pouch granuloma. Biochemical Medicine
and Metabolic Biology, 1987, 38:272–277.
23. Begum VH, Sadique J. Long term effect of herbal drug Withania somnifera
on adjuvant induced arthritis in rats. Indian Journal of Experimental Biology,
1988, 26:877–882.
24. Chaudhary G et al. Evaluation of Withania somnifera in a middle cerebral
artery occlusion model of stroke in rats. Clinical and Experimental Pharmacology
and Physiology, 2003, 30:399–404.
25. Mohanty I et al. Mechanisms of cardioprotective effect of Withania somnifera
in experimentally induced myocardial infarction. Basic and Clinical
Pharmacology and Toxicology, 2004, 94:184–190.
26. Parihar MS, Hemnani T. Phenolic antioxidants attenuate hippocampal neuronal
cell damage against kainic acid induced excitotoxicity. Journal of Bioscience,
2003, 28:121–128.
27. Bhattacharya SK et al. Effect of Withania somnifera glycowithanolides on a
rat model of tardive dyskinesia. Phytomedicine, 2002, 9:167–170.
28. Naidu PS, Singh A, Kulkarni SK. Effect of Withania somnifera root extract
on haloperidol-induced orofacial dyskinesia: possible mechanisms of action.
Journal of Medicinal Food, 2003, 6:107–114.
29. Bhattacharya SK, Stayan KS, Ghosal S. Antioxidant activity of glycowithanolides
from Withania somnifera. Indian Journal of Experimental Biology,
1997, 35:236–239.
30. Dhuley JN. Effect of ashwagandha on lipid peroxidation in stress-induced
animals. Journal of Ethnopharmacology, 1998, 60:173–178.
31. Panda S, Kar A. Evidence for free radical scavenging activity of Ashwagandha
root powder in mice. Indian Journal of Physiology and Pharmacology,
1997, 41:424–426.
32. Chaurasia SS, Panda S, Kar A. Withania somnifera root extract in the regulation
of lead-induced oxidative damage in male mouse. Pharmacological Research,
2000, 41:663–666.
33. Parihar MS et al. Susceptibility of hippocampus and cerebral cortex to oxidative
damage in streptozotocin treated mice: prevention by extracts of Withania
somnifera and Aloe vera. Journal of Clinical Neuroscience, 2004, 11:397–402.
34. Prakash J, Gupta SK, Dinda AK. Withania somnifera root extract prevents
DMBA-induced squamous cell carcinoma of skin in Swiss albino mice. Nutrition
and Cancer, 2002, 42:91–97.
35. Prakash J et al. Chemopreventive activity of Withania somnifera in experimentally
induced fibrosarcoma tumours in Swiss albino mice. Phytotherapy
Research, 2001, 15:240–244.
36. Dhuley JN. Nootropic-like effect of Ashwagandha (Withania somnifera L.)
in mice. Phytotherapy Research, 2001, 15:524–528.
37. Choudhary MI et al. Withanolides, a new class of natural cholinesterase inhibitors
with calcium antagonistic properties. Biochemical and Biophysical
Research Communications, 2005, 334:276–287.
391
Radix Withaniae
38. Schliebs R et al. Systemic administration of defined extracts from Withania
somnifera (Indian ginseng) and Shilajit differentially affects cholinergic but
not glutamatergic and gabaergic markers in rat brain. Neurochemistry International,
1997, 30:181–190.
39. Ziauddin M et al. Studies on the immunomodulatory effects of Ashwagandha.
Journal of Ethnopharmacology, 1996, 50:69–76.
40. Davis L, Kuttan G. Effect of Withania somnifera on cell mediated immune
responses in mice. Journal of Experimental and Clinical Cancer Research,
2002, 21:585–590.
41. Davis L, Kuttan G. Immunomodulatory activity of Withania somnifera.
Journal of Ethnopharmacology, 2000, 71:193–200.
42. Agarwal R et al. Studies on immunomodulatory activity of Withania somnifera
(Ashwagandha) extracts in experimental immune inflammation. Journal
of Ethnopharmacology, 1999, 67:27–35.
43. Davis L, Kuttan G. Suppressive effect of cyclophosphamide-induced toxicity
byWithania somnifera extract in mice. Journal of Ethnopharmacology, 1998,
62:209–214.
44. Iuvone T et al. Induction of nitric oxide synthase expression by Withania
somnifera in macrophages. Life Sciences, 2003, 72:1617–1625.
45. Kuboyama T et al. Axon- or dendrite-predominant outgrowth induced by
constituents from Ashwagandha. Neuroreport, 2002, 13:1715–1720.
46. Ahmad M et al. Neuroprotective effects of Withania somnifera on 6-hydroxydopamine
induced Parkinsonism in rats. Human and Experimental
Toxicology, 2005, 24:137–147.
47. Malhotra CL et al. Studies on Withania ashwagandha, Kaul. IV. The effect of
total alkaloids on the smooth muscles. Indian Journal of Physiology and
Pharmacology, 1965, 9:9–15.
48. Singh N et al. Withania Somnifera (Ashwagandha), a rejuvenating herbal
drug which enhances survival during stress (an adaptogen). International
Journal of Crude Drug Research, 1982, 20:29–35.